Approaching Rare Disease as Common and Common Disease with Precision

Christopher Austin, CEO of Vesalius Therapeutics and CEO-Partner, Flagship Pioneering, Jason Park, CEO of Empress Therapeutics and Operating Partner, Flagship Pioneering, and Michelle Werner, CEO of Alltrna and CEO-Partner, Flagship Pioneering join Robert Plenge, Executive Vice President, Chief Research Officer, Head of Research, Bristol Myers Squibb to discuss the opportunities for bioplatforms to dramatically scale the creation of new medicines and put the treatment of rare and ultra-rare diseases within reach while also finding novel ways to treat common diseases with a level of precision that, for the last two decades, has been reserved for rare diseases. More from Flagship @ JPM2024 here.